Increased EHD1 in non-small cell lung cancer predicts poor survival
Hailing Lu
The Forth Department of Medical Oncology, The Tumor Hospital of Harbin Medical University, Harbin, China
These authors contributed equally to this work.Search for more papers by this authorQingwei Meng
The Forth Department of Medical Oncology, The Tumor Hospital of Harbin Medical University, Harbin, China
These authors contributed equally to this work.Search for more papers by this authorYuan Wen
The Forth Department of Medical Oncology, The Tumor Hospital of Harbin Medical University, Harbin, China
These authors contributed equally to this work.Search for more papers by this authorJing Hu
The Forth Department of Medical Oncology, The Tumor Hospital of Harbin Medical University, Harbin, China
Search for more papers by this authorYanbin Zhao
The Forth Department of Medical Oncology, The Tumor Hospital of Harbin Medical University, Harbin, China
Search for more papers by this authorCorresponding Author
Li Cai
The Forth Department of Medical Oncology, The Tumor Hospital of Harbin Medical University, Harbin, China
Correspondence
Li Cai, The Forth Department of Medical Oncology, The Tumor Hospital of Harbin Medical University, 150 Haping Road, Harbin, Heilongjiang 150040, China.
Tel: +86 451 86298283
Fax: +86 451 86298735
Email: [email protected], [email protected]
Search for more papers by this authorHailing Lu
The Forth Department of Medical Oncology, The Tumor Hospital of Harbin Medical University, Harbin, China
These authors contributed equally to this work.Search for more papers by this authorQingwei Meng
The Forth Department of Medical Oncology, The Tumor Hospital of Harbin Medical University, Harbin, China
These authors contributed equally to this work.Search for more papers by this authorYuan Wen
The Forth Department of Medical Oncology, The Tumor Hospital of Harbin Medical University, Harbin, China
These authors contributed equally to this work.Search for more papers by this authorJing Hu
The Forth Department of Medical Oncology, The Tumor Hospital of Harbin Medical University, Harbin, China
Search for more papers by this authorYanbin Zhao
The Forth Department of Medical Oncology, The Tumor Hospital of Harbin Medical University, Harbin, China
Search for more papers by this authorCorresponding Author
Li Cai
The Forth Department of Medical Oncology, The Tumor Hospital of Harbin Medical University, Harbin, China
Correspondence
Li Cai, The Forth Department of Medical Oncology, The Tumor Hospital of Harbin Medical University, 150 Haping Road, Harbin, Heilongjiang 150040, China.
Tel: +86 451 86298283
Fax: +86 451 86298735
Email: [email protected], [email protected]
Search for more papers by this authorAbstract
Background
One of the main challenges of lung cancer research is identifying patients at high risk for recurrence after surgical resection. We evaluated the prognostic power of four proteins in the endocytic pathway in 114 non-small cell lung cancer patients (NSCLC).
Methods
We tested the four proteins (epidermal growth factor receptor [EGFR], RAB11FIP3, EHD1, and caveolin-1), critical nodes in the endocytosis/recycling pathway, by immunohistochemistry in paraffin sections from 114 non-small cell lung cancer patients. We analyzed the correlation between our target proteins and clinical variables. Within these variables, an overall survival (OS) prediction model was constructed using Cox proportional hazard regression.
Results
EHD1 expression correlated with gender (P = 0.001), histology type (P < 0.001), and EGFR expression (P = 0.008), but not with any of the other clinical parameters. Statistical correlation analysis showed that the expression of EHD1 positively correlated with high level of EGFR (P < 0.001) and RAB11FIP3 (P < 0.001), and the expression of caveolin-1 positively correlated with high level of EGFR (P < 0.001) in the NSCLC samples. EHD1 expression was an OS prognostic factor for all of the patients (P = 0.009), for the group of adjuvant chemotherapy-treated patients (P = 0.006), and for the EGFR positive patients (P = 0.034).
Conclusions
We identified EHD1 as a strong prognostic predictive factor in NSCLC. The expression level of EHD1 would potentially be useful in developing customized strategies for managing lung cancer, such as the selection of patients eligible for chemotherapy.
References
- 1 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10–29.
- 2 Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K, American College of Chest Physicians. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132 (Suppl. 3): 234S–242.
- 3 Suzuki K, Kachala SS, Kadota K et al. Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res 2011; 17: 5247–5256.
- 4 Botling J, Edlund K, Lohr M et al. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res 2013; 19: 194–204.
- 5 Lee ES, Son DS, Kim SH et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res 2008; 14: 7397–7404.
- 6 Guo NL, Wan YW, Tosun K et al. Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res 2008; 14: 8213–8220.
- 7 Sun Z, Wigle DA, Yang P. Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol 2008; 26: 877–883.
- 8 Beer DG, Kardia SL, Huang CC et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8: 816–824.
- 9 Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 2010; 102: 464–474.
- 10 Van Damme V, Govaerts E, Nackaerts K, Dooms C, Wauters I, Vansteenkiste J. Clinical factors predictive of long-term survival in advanced non-small cell lung cancer. Lung Cancer 2013; 79: 73–76.
- 11 Cioffi P, Marotta V, Fanizza C et al. Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study. J Oncol Pharm Pract 2013; 19: 246–253.
- 12 Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004; 59 (Suppl. 2): 21–26.
- 13 Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127–137.
- 14 Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Cancer 2007; 7: 169–181.
- 15 Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer 2008; 8: 835–850.
- 16 Maxfield FR, McGraw TE. Endocytic recycling. Nat Rev Mol Cell Biol 2004; 5: 121–132.
- 17 Alwan HA, van Zoelen EJ, van Leeuwen JE. Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. J Biol Chem 2003; 278: 35781–35790.
- 18 Stern KA, Visser Smit GD, Place TL, Winistorfer S, Piper RC, Lill NL. Epidermal growth factor receptor fate is controlled by Hrs tyrosine phosphorylation sites that regulate Hrs degradation. Mol Cell Biol 2007; 27: 888–898.
- 19 Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 2003; 422 (6927): 37–44.
- 20 Hendriks BS, Wiley HS, Lauffenburger D. HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanisms. Biophys J 2003; 85: 2732–2745.
- 21 Shankaran H, Zhang Y, Opresko L, Resat H. Quantifying the effects of co-expressing EGFR and HER2 on HER activation and trafficking. Biochem Biophys Res Commun 2008; 371: 220–224.
- 22 Offterdinger M, Bastiaens PI. Prolonged EGFR signaling by ERBB2-mediated sequestration at the plasma membrane. Traffic 2008; 9: 147–155.
- 23 Chung BM, Raja SM, Clubb RJ et al. Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src. BMC Cell Biol 2009; 10: 84.
- 24 Naslavsky N, Caplan S. EHD proteins: key conductors of endocytic transport. Trends Cell Biol 2011; 21: 122–131.
- 25 Lin SX, Grant B, Hirsh D, Maxfield FR. Rme-1 regulates the distribution and function of the endocytic recycling compartment in mammalian cells. Nat Cell Biol 2001; 3: 567–572.
- 26 Caplan S, Naslavsky N, Hartnell LM et al. A tubular EHD1-containing compartment involved in the recycling of major histocompatibility complex class I molecules to the plasma membrane. EMBO J 2002; 21: 2557–2567.
- 27 Jovic M, Naslavsky N, Rapaport D, Horowitz M, Caplan S. EHD1 regulates beta1 integrin endosomal transport: effects on focal adhesions, cell spreading and migration. J Cell Sci 2007; 120: 802–814.
- 28 Naslavsky N, Rahajeng J, Sharma M, Jovic M, Caplan S. Interactions between EHD proteins and Rab11-FIP2: a role for EHD3 in early endosomal transport. Mol Biol Cell 2006; 17: 163–177.
- 29 Sato M, Sato K, Liou W, Pant S, Harada A, Grant BD. Regulation of endocytic recycling by C. elegans Rab35 and its regulator RME-4, a coated-pit protein. EMBO J 2008; 27: 1183–1196.
- 30 Gokool S, Tattersall D, Seaman MN. EHD1 interacts with retromer to stabilize SNX1 tubules and facilitate endosome-to-Golgi retrieval. Traffic 2007; 8: 1873–1886.
- 31 Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell 2008; 15: 209–219.
- 32 Nishimura Y, Bereczky B, Ono M. The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines. Histochem Cell Biol 2007; 127: 541–553.
- 33 Naslavsky N, Caplan S. C-terminal EH-domain-containing proteins: consensus for a role in endocytic trafficking, EH? J Cell Sci 2005; 118: 4093–4101.
- 34 Lee DW, Zhao X, Scarselletta S et al. ATP binding regulates oligomerization and endosome association of RME-1 family proteins. J Biol Chem 2005; 280: 17213–17220.
- 35 Daumke O, Lundmark R, Vallis Y, Martens S, Butler PJ, McMahon HT. Architectural and mechanistic insights into an EHD ATPase involved in membrane remodelling. Nature 2007; 449 (7164): 923–927.
- 36 Galperin E, Benjamin S, Rapaport D, Rotem-Yehudar R, Tolchinsky S, Horowitz M. EHD3: a protein that resides in recycling tubular and vesicular membrane structures and interacts with EHD1. Traffic 2002; 3: 575–589.
- 37 George M, Ying G, Rainey MA et al. Shared as well as distinct roles of EHD proteins revealed by biochemical and functional comparisons in mammalian cells and C. elegans. BMC Cell Biol 2007; 8: 3.
- 38 Sharma M, Naslavsky N, Caplan S. A role for EHD4 in the regulation of early endosomal transport. Traffic 2008; 9: 995–1018.
- 39 Mintz L, Galperin E, Pasmanik-Chor M et al. EHD1–an EH-domain-containing protein with a specific expression pattern. Genomics 1999; 59: 66–76.
- 40 Salcini AE, Confalonieri S, Doria M et al. Binding specificity and in vivo targets of the EH domain, a novel protein-protein interaction module. Genes Dev 1997; 11: 2239–2249.
- 41 Soldati T, Schliwa M. Powering membrane traffic in endocytosis and recycling. Nat Rev Mol Cell Biol 2006; 7: 897–908.
- 42 Grant BD, Caplan S. Mechanisms of EHD/RME-1 protein function in endocytic transport. Traffic 2008; 9: 2043–2052.
- 43 Rahajeng J, Giridharan SS, Naslavsky N, Caplan S. Collapsin response mediator protein-2 (Crmp2) regulates trafficking by linking endocytic regulatory proteins to dynein motors. J Biol Chem 2010; 285: 31918–31922.
- 44 Rainey MA, George M, Ying G et al. The endocytic recycling regulator EHD1 is essential for spermatogenesis and male fertility in mice. BMC Dev Biol 2010; 10: 37.
- 45 Hansel DE, Rahman A, House M et al. Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Clin Cancer Res 2004; 10: 6152–6158.
- 46 Jansen FH, Krijgsveld J, van Rijswijk A et al. Exosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins. Mol Cell Proteomics 2009; 8: 1192–1205.
- 47 Shin J, Monti S, Aires DJ et al. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood 2007; 110: 3015–3027.
- 48 Wu ZZ, Lu HP, Chao CC. Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells. Biochem Pharmacol 2010; 80: 262–276.
- 49 Naslavsky N, Rahajeng J, Rapaport D, Horowitz M, Caplan S. EHD1 regulates cholesterol homeostasis and lipid droplet storage. Biochem Biophys Res Commun 2007; 357: 792–799.
- 50 Yap CC, Lasiecka ZM, Caplan S, Winckler B. Alterations of EHD1/EHD4 protein levels interfere with L1/NgCAM endocytosis in neurons and disrupt axonal targeting. J Neurosci 2010; 30: 6646–6657.
- 51 Wang Y, Pennock S, Chen X, Wang Z. Endosomal signaling of epidermal growth factor receptor stimulates signal transduction pathways leading to cell survival. Mol Cell Biol 2002; 22: 7279–7290.
- 52 Pennock S, Wang Z. Stimulation of cell proliferation by endosomal epidermal growth factor receptor as revealed through two distinct phases of signaling. Mol Cell Biol 2003; 23: 5803–5815.
- 53 Rotem-Yehudar R, Galperin E, Horowitz M. Association of insulin-like growth factor 1 receptor with EHD1 and SNAP29. J Biol Chem 2001; 276: 33054–33060.
- 54 Guilherme A, Soriano NA, Furcinitti PS, Czech MP. Role of EHD1 and EHBP1 in perinuclear sorting and insulin-regulated GLUT4 recycling in 3T3-L1 adipocytes. J Biol Chem 2004; 279: 40062–40075.
Citing Literature
